

Index

- Acetyl linkage in aspirin* 51
Acid secretory capacity 67
β-Adrenoceptor blockers 3
Adrenoceptor stimulation 607
α₂-Adrenoceptor agonists and antagonist 649
Adrian, T. E. *see* Fuessl, H. S.
Adverse reaction 201
Allen, M., Mellow, M., Robinson, M. G. & Orr, W. C.
Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function 153
Allison, M. C. & Pounder, R. E. Cyclosporin for Crohn's disease 39
5-Aminosalicylic acid, 201, 209, 273
Anderson, J. V. *see* Fuessl, H. S.
Antidepressants 141
Antisecretory drugs 77
Aspirin-induced gastric mucosal damage, 383
Axelson, M. *see* Sharma, B.
Axon, A. T. R. *see* Burke, D. A.

Back, D. J. & Rogers, S. M. Review: first-pass metabolism by the gastrointestinal mucosa 339
Ball, S. *see* Lanzon-Miller, S.
Barnett, C. C. *see* Richardson, C. T.
Barry, M. *see* Macmathuna, P.
Basolateral vesicles 415
Baxter, A. J., Edwards, C. A., Holden, S., Cunningham, K. M., Welch, I. M. L. & Read, N. W. The effect of two α₂-adrenoceptor agonists and an antagonist on gastric emptying and mouth to caecum transit time in humans 649
Baxter, A. J. *see* Welch, I. M. L.
Beil, W., Stünkel, P., Pieper, A. & Sewing, K.-FR. The gastric proton pump, a target for neuroleptics and antidepressant drugs? 141
Bennett, A. *see* Tavares, I. A.
Bianchi Porro, G., Pace, F. & Caruso, I. Why are non-steroidal anti-inflammatory drugs important in peptic ulceration 540 S

Bloom, S. R. *see* Fuessl, H. S.
Bloom, S. R. *see* Savage, A. P.
Blum, A. L. *see* Bumm, R.
Boyd, E. J. S., Johnston, D. A., Wormsley, K. G., Jenner, W. N. & Salanson, X. The effects of cigarette smoking on plasma concentrations of gastric antisecretory drugs 57
Brook, C. W., Yeomans, N. D., Hewson, E. G. & Smallwood, R. A. Gastric acid secretory capacity falls under repeated within-day pentagastrin testing in fed subjects 253
Brook, M. G., Dunk, A. A., McDonald, J. A., Lever, A. M., Goh, C. & Thomas, H. C. Human lymphoblastoid interferon does not increase survival when added to mitozantrone in the treatment of hepatocellular carcinomas 315
Brush border 415
Bullimore, D. W., Mulley, B. A., Cooke, P. & Miloszewski, K. J. A. Comparison of the effectiveness of midazolam and diazepam in lipid emulsion as sedation during gastrointestinal endoscopy 409
Bumm, R. & Blum, A. L. Lessons from prolonged gastric pH monitoring 518 S
Burget, D. W. *see* De Gara, C. J.
Burget, D. W. *see* Howden, C. W.
Burke, D. A., Manning, A. P., Williamson, J. M. S. & Axon, A. T. R. Adverse reactions to sulphasalazine and 5-aminosalicylic acid in the same patient 201
Burrin, J. M. *see* Fuessl, H. S.
Burroughs, A. K., Sprengers, D. & McCormick, P. A. Review article: β-adrenoceptor blockers for the treatment of portal hypertension 3

Calarm, J. *see* Savage, A. P.
Calmodulin antagonists 415
Calcium transport 415
Caruso, I. *see* Branchi Porro, G.
Campylobacter pylori 527 S
Cancer 133

- Cederberg, C. *see* Lanzon-Miller, S.
 Cederberg, C. *see* Sharma, B.
Cellular effects 77
 Chakraborty, T. K., De Caestecker, J. S., Pryde, A. & Heading, R. C. Effect of omeprazole on lower oesophageal function in normal subjects 627
Cholecystitis 607
Choline and magnesium moieties 51
Cholinoreceptor stimulation 607
 Chremos, A. N. *see* De Gara, C. J.
 Chronos, N. A. F. *see* Lanzon-Miller, S.
Cigarette smoking 57
Cimetidine 23, 167, 367, 369, 383, 401
Cirrhosis 639
Cisapride 293
 Clanahan, A. S. *see* Feeley, T. M.
 Clark, A. G. *see* Reynolds, J. R.
Clinical trials 91
 Colin-Jones, D. G. When should endoscopy (or radiology) be used in dyspepsia and peptic ulcer disease? 548 S
 Colin-Jones, D. G., Langman, M. J. S., Lawson, D. H. & Vessey, M. P. Review: post-marketing surveillance of the safety of cimetidine—the problems of data interpretation 167
 Collins, P. O. *see* Tavares, I. A.
Colon 133
Colonic transit 293
Constipation 331
 Cooke, P. *see* Bullimore, D. W.
Crohn's disease 39, 391
 Cunningham, K. M. *see* Baxter, A. J.
Cyclosporin 39
 Dammann, H. G., Walter, Th. A., Dreyer, M., Dau, B., Müller, P. & Simon, B. What are the current possibilities in treating peptic ulcer disease? 468 S
 Danesh, B. J. Z., Nelson, L. M., Russell, R. I. & Docherty, C. Replacing the acetyl linkage in aspirin with choline and magnesium moieties reduces the occurrence of gastric mucosal injury 51
 De Caestecker, J. S. *see* Chakraborty, T. K.
Decision making 91
 De Gara, C. J., Burget, D. W., Chremos, A. N., Silletti, C. & Hunt, R. H. The effects of intravenous famotidine on pentagastrin-stimulated gastric secretion 125
Diarrhoea 179
Diazepam 409
Diltiazem 153
 Docherty, C. *see* Danesh, B. J. Z.
 Domin, J. *see* Fuessl, H. S.
Domperidone 425
 Domschke, W. *see* Stoll, R.
Drug absorption 391
 Dunk, A. A. *see* Brook, M. G.
Duodenal ulcer 91, 161, 217, 225
Duodenal ulcer disease 281
Duodenum 415
Dyspepsia 548 S
 Edwards, C. A. *see* Baxter, A. J.
 Eigenmann, F. *see* Halter, F.
Endogenous antibodies 51
Endoscopy 409, 548 S
Eniprost 305
Enprostil 161
Enteric-coated tablet 209, 273
Epidemiology of peptic ulcer 510 S
Famotidine 125, 504 S
 Feeley, T. M., Clanahan, A. S. & Scott, G. W. Contractility of human gallbladder muscle *in vitro* 607
 Feely, J. *see* Macmathuna, P.
 Feldman, M. *see* Richardson, C. T.
First-pass metabolism 339
 Fisher, R. S. *see* Kreusky, B.
 Fotherby, K. J. & Hunter, J. O. Idiopathic slow-transit constipation: whole gut transit times, measured by a new simplified method, are not shortened by opioid antagonists 331
 Fuessl, H. S., Burrin, J. M., Williams, G. M., Adrian, T. E. & Bloom, S. R. The effect of a long-acting somatostatin analogue (SMS 201-995) on intermediary metabolism and gut hormones after a test meal in normal subjects 321
 Fuessl, H. S., Domin, J., Anderson, J. V. & Bloom, S. R. Chronic administration of the somatostatin analogue SMS 201-995 does not lead to endogenous antibody formation 45
Gallbladder motility 607
Gastric acid 253, 281, 305, 643
Gastric antisecretory drugs 57
Gastric emptying 401, 425, 649
Gastric mucosa 617
Gastric mucosal injury 593
Gastric ulcer 225, 633
Gastrointestinal bleeding 23
Gastrointestinal mucosa 339
 Goh, C. *see* Brook, M. G.
Gut hormones 321
Gut sterilization 359

- Halter, F. & Eigenmann, F. Is it really more difficult to treat prepyloric ulcers? 433 S
- Hameeteman, W. *see* Tytgat, G. N. J.
- Hamilton, M. R. *see* Lanzon-Miller, S.
- Hardcastle, J. D. *see* Reynolds, J. R.
- Hardy, J. C., Healey, J. N. C., Lee, S. W. & Reynolds, J. R. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet 209
- Hardy, J. G., Healey, J. N. C. & Reynolds, J. R. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease 273
- Hawkey, C. J. Review: acute human models of gastric mucosal injury 593
- Hawkey, C. J. *see* Walt, R. P.
- Heading, R. C. *see* Chakraborty, T. K.
- Healey, J. N. C. *see* Hardy, J. G.
- Heart rate 281
- Heim, J. *see* Walt, R. P.
- Hepatocellular carcinomas* 315
- Hewson, E. G. *see* Brook, C. W.
- Hodgson, H. J. F. Review: gut sterilization in inflammatory bowel disease 359
- Hogan, D. L., Thomas, F. J. & Isenberg, J. I. Cimetidine decreases aspirin-induced gastric mucosal damage in humans 383
- Holden, S. *see* Baxter, A. J.
- Houghton, L. A. & Read, N. W. A comparative study of the effect of cimetidine and ranitidine on the rate of gastric emptying of liquid and solid test meals in man 401
- Howden, C. W., Burget, D. W., Silletti, C., Van Eeden, A., Tomkins, K. B. & Hunt, R. H. Marked suppression of stimulated gastric acid and pepsin secretion by eniprostol, a new PGE₁ analogue 305
- H₂-receptor antagonists 493 S, 447 S
- H⁺ secretion 141
- Human 607
- Hunt, R. H. *see* De Gara, C. J.
- Hunt, R. H. *see* Howden, C. W.
- Hunter, J. O. *see* Fotherby, K. J.
- Hyoscyamine* 153
- Idazoxan* 425
- Ideal lipid* 425
- Inflammatory bowel disease* 273, 359
- Interferon* 315
- Intermediary metabolism* 321
- Intractable duodenal ulcer* 439 S
- Intragastric acidity* 217, 225, 239
- Isenberg, J. I. The impact of H₂-receptor antagonists on the complications, morbidity and mortality of peptic ulcer disease 447 S
- Isenberg, J. I. *see* Hogan, D. L.
- Jansen, J. M. B. J. *see* Tytgat, G. N. J.
- Jenner, W. N. *see* Boyd, E. J. S.
- Johnston, D. A. *see* Boyd, E. J. S.
- K⁺/H⁺-ATPase 141
- Kaufmann, D. *see* Merki, H. S.
- Keeling, P. W. N. *see* Kennedy, N. P.
- Keeling, P. W. N. *see* Macmathuna, P.
- Kelleher, D. *see* Macmathuna, P.
- Kennedy, N. P. & Keeling, P. W. N. Review: lipoxygenase inhibitors and the gut 263
- Krevsky, B., Malmud, L. S., Maurer, A. H., Somers, M. B., Siegel, J. A. & Fisher, R. S. The effect of oral cisapride on colonic transit 293
- Lamers, C. B. H. W. *see* Tytgat, G. N. J.
- Langman, M. J. S. Editorial comment 367
- Langman, M. J. S. *see* Colin-Jones, D. G.
- Langman, M. J. S. *see* Pounder, R. E.
- Langman, M. J. S. *see* Reynolds, J. R.
- Langman, M. J. S. *see* Walt, R. P.
- Lanzon-Miller, S., Pounder, R. E., Hamilton, M. R., Chronos, N. A. F., Ball, S., Mercieca, J. E., Olausson, M. & Cederberg, C. Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer or pernicious anaemia 225
- Lanzon-Miller, S., Pounder, R. E., Hamilton, M. R., Ball, S., Chronos, N. A. F., Raymond, F., Olausson, M. & Cederberg, C. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole 239
- Lauritsen, K. & Rask-Madsen, J. Review: clinical trials in peptic ulcer disease—problems of methodology and interpretation, 91
- Lawson, D. H. *see* Colin-Jones, D. G.
- Lee, S. W. *see* Hardy, J. G.
- Lennard-Jones, J. E. *see* Rodrigues, C. A.
- Lever, A. M. *see* Brook, M. G.
- Lipoxygenase inhibitors* 263
- Logan, R. F. A. *see* Walt, R. P.
- Long, R. G. Review: long-acting somatostatin analogues 191
- Long, R. G. *see* Walt, R. P.
- Long-term treatment* 45
- Loperamide* 179

660 INDEX

- Lower oesophageal sphincter pressure* 627
Lundborg, P. *see* Sharma, B.
- Macmathuna, P., O'Reilly, T., Kelleher, D., Barry, M., Feely, J. & Keeling, P. W. N. The effect of calcium channel blockade with nifedipine on splanchnic and systemic haemodynamics in cirrhosis 639
- Maintenance therapy* 633
Malmud, L. S. *see* Krevsky, B.
- Manometry* 153
Mann, S. G. The place of famotidine in anti-ulcer therapy 504 S
- Manning, A. P. *see* Burke, D. A.
- Mappes, A. *see* Merki, H. S.
- Maurer, A. H. *see* Krevsky, B.
- McAdam, W. A. F. *see* Morgan, A. G.
- McCanless, I. *see* McIsaac, R. L.
- McCormick, P. A. *see* Burroughs, A. K.
- McDonald, J. A. *see* Brook, M. G.
- McIntyre, P. B. *see* Rodrigues, C. A.
- McIsaac, R. L., McCanless, I., Summers, K. & Wood, J. R. Ranitidine and cimetidine in the healing of duodenal ulcer: meta-analysis of comparative clinical trials 369
- Mellow, M. *see* Allen, M.
- Mercieca, J. E. *see* Lanzon-Miller, S.
- Merki, H. S., Witzel, L., Walt, R. P., Neumann, J., Scheurle, E., Kaufmann, D., Mappes, A., Heim, J. & Röhmel, J. Comparison of ranitidine 300 mg twice daily, 300 mg at night and placebo on 24-hour intragastric acidity of duodenal ulcer patients 217
- Midazolam* 409
- Miloszewski, K. J. A. *see* Bullimore, D. W.
- Misiewicz, J. J. What is new in the epidemiology and pathogenesis of peptic ulcer? 510 S
- Mitoxantrone* 315
- Morgan, A. G., Pacsoo, C., Taylor, P. & McAdam, W. A. F. Does Caved-S decrease the gastric ulcer relapse rate during maintenance treatment with ranitidine 633
- Motility* 179
- Mouth to caecum transit time* 649
- Mulley, B. A. *see* Bullimore, D. W.
- Nabi, E. M. *see* Rodrigues, C. A.
- Naloxone* 425
- Nelson, L. M. *see* Danesh, B. J. Z.
- Neumann, J. *see* Merki, H. S.
- Neuroleptics* 141
- Nicardipine* 643
- Nifedipine* 153, 639
- Non-steroidal anti-inflammatory drugs* 540 S, 617
- Northfield, T. C. *see* Zentler-Munro, P. L.
- Oesophageal motility* 627
- Oesophagus* 153
- Öhman, M. *see* Sharma, B.
- Olausson, M. *see* Lanzon-Miller, S.
- omeprazole* 31, 67, 239, 627
- Opiates* 179
- Opioid antagonists* 331
- Opioids* 179
- O'Reilly, T. *see* Macmathuna, P.
- Orr, W. C. *see* Allen, M.
- Pace, F. *see* Bianchi Porro, G.
- Pacsoo, C. *see* Morgan, A. G.
- Pancreas* 133
- Pancreatic endocrine tumours* 45
- Pancreatic enzyme replacement* 575
- Panel discussions* 556 S
- Parietal cells* 141
- Pathogenesis of peptic ulcer* 510 S
- Pentagastrin* 253
- Pentagastrin-stimulated gastric secretion* 125
- Pepsin secretion* 305
- Peptic ulcer* 31, 91, 510 S, 540 S
- Peptic ulcer disease* 447 S, 468 S, 548 S
- Peptic ulcer haemorrhage* 91
- Peptides* 607
- Pernicious anaemia* 225
- PGE₁ analogue* 305
- pH monitoring* 23, 518 S
- Phongsathorn, V. *see* Rodrigues, C. A.
- Pirenzipine* 281
- Placebo* 217
- Plasma gastrin* 67, 225, 239
- Porta hypertension* 3
- Post-marketing surveillance* 167
- Pounder, R. E. & Langman, M. J. S. Letter from the *Editor* 1
- Pounder, R. E. P. & Langman, M. J. S. Letter from the *Editors* 261
- Pounder, R. E. What is an intractable duodenal ulcer and how should it be managed? 439 S
- Pounder, R. E. *see* Allison, M. C.
- Pounder, R. E. *see* Lanzon-Miller, S.
- Pounder, R. E. *see* Sharma, B.
- Pounder, R. E. *see* Walt, R. P.
- Prednisolone* 391
- Prepyloric ulcers* 435 S
- Prior, A. & Whorwell, P. J. Effect of nicardipine on gastric acid secretion in man 643
- Prolonged gastric pH monitoring* 518 S
- Propantheline* 281

- Prostaglandins* 617
Pryde, A. see Chakraborty, T. K.
- Radiology* 548 S
Ranitidine 23, 161, 217, 239, 367, 369, 401, 633
Ranitidine plus Caved-S 633
Rask-Madsen, J. see Lauritsen, K.
Rauws, E. A. J. see Tytgat, G. N. J.
Raymond, F. see Lanzon-Miller, S.
Read, N. W. see Baxter, A. J.
Read, N. W. see Houghton, L. A.
Read, N. W. see Welch, I. M. L.
Refractory peptic ulcer 31
Research design 91
Reynolds, J. R., Walt, R. P., Clark, A. G., Hardcastle, J. D. & Langman, M. J. S. Intragastric pH monitoring in acute upper gastrointestinal bleeding and the effect of intravenous cimetidine and ranitidine 23
Reynolds, J. R. see Hardy, J. G.
Richardson, C. T., Barnett, C. C., Walsh, J. H. & Feldman, M. Comparison of two antimuscarinic drugs, pirenzapine and propantheline, on gastric acid secretion, salivary flow and heart rate in patients with duodenal ulcer disease 281
Robinson, M. G. see Allen, M.
Rodrigues, C. A., Nabi, E. M., Spiliadis, C., McIntyre, P. B., Phongsathorn, V., Lennard-Jones, J. E., Rosen, A. & Willoughby, J. M. T. Prednisolone absorption in inflammatory bowel disease: correlation with anatomical site and extent 391
Rogers, S. M. see Back, D. J.
Röhmel, J. see Walt, R. P.
Rosen, A. see Rodrigues, C. A.
Ruppin, H. Review: Loperamide—a potent anti-diarrhoeal drug with actions along the alimentary tract 179
Ruppin, H. see Stoll, R.
Russell, R. L. see Danesh, B. J. Z.
- Salanson, X.* see Boyd, E. J. S.
Salivary flow, 281
Santana, A. see Sharma, B.
Santana, I. A. see Walt, R. P.
Savage, A. P., Calam, J., Wood, C. B. & Bloom, S. R. SMS 201-995 treatment and advanced intestinal cancer: a pilot study, 133
Scheurle, E. see Merki, H. S.
Schunak, W. What are the differences between the H_2 -receptor antagonists? 493 S
Scott, G. W. see Feeley, T. M.
Sharma, B., Axelson, M., Pounder, R. E., Lundborg, P.,
- Öhman, M., Santana, A., Talbot, M. & Cederberg, C.* Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects 67
Siegel, J. A. see Krevsky, B.
Silletti, C. see De Garda, C. J.
Silletti, C. see Howden, C. W.
Smallwood, R. A. see Brook, C. W.
SMS 201-995 133, 321
Somatostatin 133
Somatostatin analogue 45, 179, 321
Somers, M. B. see Krevsky, B.
Somerville, K. W. see Walt, R. P.
Soll, A. H. Review: antisecretory drugs—cellular mechanisms of action 77
Spiliadis, C. see Rodrigues, C. A.
Splanchnic and systemic haemodynamics 639
Sprengers, D. see Burroughs, A. K.
Stern, H. see Stoll, R.
Stoll, R., Stern, H., Ruppin, H. & Domschke, W. Effect of two potent calmodulin antagonists on calcium transport of brush border and basolateral vesicles from human duodenum 415
Stomach 133
Stomach ulcer 91
Sulphasalazine 201
Summers, K. see McIsaac, R. L.
Swain, C. P. When and why do ulcers bleed and what can be done about it? 455 S
- Talbot, M.* see Sharma, B.
Tavares, I. A., Collins, P. O. & Bennett, A. Inhibition of prostanoïd synthesis by human gastric mucosa 617
Taylor, P. see Morgan, A. G.
Thomas, F. J. see Hogan, D. L.
Thomas, H. C. see Brook, M. G.
Tomkins, K. B. see Howden, C. W.
Thromboxanes 617
Transport 179
Tytgat, G. N. J., Lamers, C. B. H. W., Hameeteman, W., Jansen, J. M. B. J. & Wilson, J. A. Omeprazole in peptic ulcers resistant to histamine H_2 -receptor antagonists 31
Tytgat, G. N. J. & E. A. J. Rauws Significance of *Campylobacter pylori* 527 S
- Ulcerative colitis* 391
Van Eeden, A. see Howden, C. W.
Verapamil 153
Vessey, M. P. see Colin-Jones, D. G.

662 INDEX

- Walsh, J. H. *see* Richardson, C. T.
Walt, R. P., Pounder, R. E., Hawkey, C. J., Santana, I. A., Somerville, K. W., Logan, R. F. A., Long, R. G. & Langman, M. J. S. Twenty-four-hour intragastric acidity and clinical trial of bedtime enprostil 70 µg compared with ranitidine 300 mg in duodenal ulcer 161
Walt, R. P. *see* Merki, H. S.
Walt, R. P. *see* Reynolds, J. R.
Welch, I. M. L., Baxter, A. J. & Read, N. W. Effect of naloxone, domperidone and idazoxan on the delay in gastric emptying induced by ileal lipid 425
Welch, I. M. L. *see* Baxter, A. J.
Whole gut transit time 331
Whorwell, P. J. *see* Prior, A.
Williams, G. M. *see* Fuessl, H. S.
Williamson, J. M. S. *see* Burke, D. A.
Willoughby, J. M. T. *see* Rodrigues, C. A.
Wilson, J. A. *see* Tytgat, G. N. J.
Witzel, L. *see* Merki, H. S.
Wood, C. B. *see* Savage, A. P.
Wood, J. R. *see* McIsaac, R. L.
Wormsley, K. G. *see* Boyd, E. J. S.
Yeomans, N. D. *see* Brook, C. W.
Zentler-Munro, P. L. & Northfield, T. C. Review: pancreatic enzyme replacement—applied physiology and pharmacology 575

